Clifford Chance

Freshfields and Clifford Chance Advise on UCB’s $680 Million Sale Paid Members Public

In Short: Belgian biopharma giant UCB is selling its portfolio of established products in China, including epilepsy drug Keppra and antihistamine Zyrtec, to Singapore's CBC Group and Abu Dhabi’s Mubadala Investment Co. for $680 million. This move allows UCB to focus on developing new medicines in China,